Morgan Stanley Starts Optimer Pharmaceuticals (OPTR) at Underweight
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 18 | New: 19
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 18 | New: 19
Join SI Premium – FREE
Optimer Pharmaceuticals (NASDAQ: OPTR) is getting wrecked today after Morgan Stanley initiated coverage on the stock with a dreaded 'Underweight' rating and downside price target of $11 price target, or 14 percent Wednesday's close.
The firm said reimbursement hurdles, sluggish launch trends, and a lack of clear long-term growth drivers limit sales expectations for Dificid.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals last traded at $11.90, down 7 percent.
The firm said reimbursement hurdles, sluggish launch trends, and a lack of clear long-term growth drivers limit sales expectations for Dificid.
For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals last traded at $11.90, down 7 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Starts Nebius Group (NBIS) at Neutral
- Benchmark Starts Inflection Point Acquisition Corp V (IPEX) at Buy
- Morgan Stanley Resumes QXO Inc (QXO) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
